Latest Breaking News On - Matt pera - Page 3 : comparemela.com

EyeBio Announces Expansion of Series A to $130 Million, Advances Development of Restoret for Retinal

EyeBio doubles the size of its original Series A raise with an additional $65 million, with new investors Bain Capital Life Sciences, Omega Funds and Vertex Ventures HC joining the round to support accelerated development of its innovative retinal disease pipelineCompletes enrollment of Multiple Ascending Dose phase.

United kingdomCity ofUnited statesTony adamisChristine brennanMatt peraBernard davitianDavid guyerBain capital life sciencesEyebiotech limited eyebioVentures fundMerck co incSv health investorsEyebio eyebiotechOmega fundsVertex ventures

Inozyme Pharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights

– Patient recruitment underway in ENERGY-3 Pivotal Trial of INZ-701 in pediatric patients with ENPP1 Deficiency; topline data expected mid-2025 –

United statesStefan rileyDouglasa trecoInozyme pharmaMatt peraPamerican society for boneDrug administrationInozyme pharma incDevelopment rd expensesAmerican society for nephrologyPaediatric committee of the european medicines agencyMineral researchCorporate communicationsAmerican society of nephrology kidney weekExchange commissionAmerican society

Inozyme Pharma Announces Presentation at the American Society of Nephrology (ASN) Kidney Week 2023 - Inozyme Pharma (NASDAQ:INZY)

BOSTON, Oct. 26, 2023 (GLOBE NEWSWIRE) Inozyme Pharma, Inc. (NASDAQ:INZY) ("Inozyme" or the "Company"), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of

United statesInozyme pharmaSagar nigwekarStefan rileyMatt peraResearch advances in boneDrug administrationInozyme pharma incEuropean calcified tissue society congressCorporate communicationsAmerican society of nephrologyKidney research centerExchange commissionMmsc coAmerican societyKidney week

Inozyme Pharma Highlights Inclusion of Generalized Arterial Calcification of Infancy (GACI) in Genomics England s Generation Study of Rare Conditions

Inozyme Pharma Highlights Inclusion of Generalized Arterial Calcification of Infancy (GACI) in Genomics England s Generation Study of Rare Conditions
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesInozyme pharmaCatherine nesterMatt peraStefan rileyCorporate communicationsUnited kingdom national health serviceExchange commissionInozyme pharma incGeneralized arterial calcificationGenomic englandNational health serviceGenomics englandGeneration studyPrivate securities litigation reform act

Inozyme Pharma Highlights Inclusion of Generalized Arterial Calcification of Infancy (GACI) in Genomics England s Generation Study of Rare Conditions -October 10, 2023 at 08:31 am EDT

BOSTON, Oct. 10, 2023 Inozyme Pharma, Inc. , a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal.

United kingdomUnited statesInozyme pharmaCatherine nesterStefan rileyMatt peraExchange commissionUnited kingdom national health serviceCorporate communicationsInozyme pharma incGlobenewswire incGeneralized arterial calcificationGenomic englandNational health serviceGenomics englandGeneration study